The Serum Institute of India (SII) has reported relief on Monday for a country battling the Corona virus epidemic.
According to the company, the vaccine ‘Kovishield’, prepared by Oxford University-AstraZeneca, will be approved for use in January next year and the company has completed its preparation.
The company has so far produced 40–50 million (four to five crore) doses and will be the first to be given to India.
License should be available by January- Poonawala
SII Chief Executive Officer (CEO) Adar Poonawalla said, “You will hear some good news from the UK very soon. We should have an AstraZeneca / Oxford vaccine license by January.”
He added, “Once we get regulatory approval in a few days it is up to the government to decide how much it can take and how fast it can take.”
This will enable India to get the vaccine on time.
To produce 30 crore doses by July 2021 – Poonawala
Poonawala said, “SII, which manufactures Kovishield, has already produced four to five crore dosages. So we have set a target of producing 30 crore dosages by July 2021.”
He added, “The first six months of 2021 will see a global shortage and there is no solution, but by August-September 2021, other vaccine manufacturers will also be able to supply.”
Vaccine is up to 95 percent effective
On the challenges faced in the process of getting the vaccine approved, Poonawala said, “The regulatory body is studying the data. There is nothing to worry about. The vaccine is 92 to 95 percent effective.”
He added, “In Britain, the vaccine may be approved for emergency use in late December or January. It is expected to happen in India as well. We should wait for good news.”
This is the condition of corona infection in India
In India, 20,021 new cases of coronavirus infection were reported and 279 patients died.
The total number of infected people in the country has risen to 1,02,07,871. Of these, 1,47,901 have died. The number of active cases has come down to 2,77,301.
The number of infected in the country reached 20 lakh on 7 August, 30 lakh on 23 August, 5 lakh on 16 September, 80 lakh on 11 October and 10 million on 19 December.
Three companies have applied for approval in India
Apart from SII in India, Bharat Biotech and Pfizer have applied for approval to use their vaccine. Out of these, Bharat Biotech and SII have provided additional data. Statistics have not yet been provided by Pfizer.